Clinical effects of leukofiltration and surface modification on post-cardiopulmonary bypass atrial fibrillation in different risk cohorts

Perfusion

Volumn 22, Issue 4, 2007, Pages 279-288

  Gunaydin, Serdar ^a   Ayrancioglu, Kamil ^a   Dikmen, Erkan ^a   Mccusker, Kevin ^b   Vijay, Venkataramana ^c   Sari, Tamer ^d   Tezcaner, Tevfik ^d   Zorlutuna, Yaman ^d  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d BAYINDIR HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLIC ACID DERIVATIVE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; COMPLEMENT COMPONENT C3A; CREATINE KINASE MB; DIGITALIS; INTERLEUKIN 2; STEROID;

AGED; ANIMAL CELL; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; COMPLEMENT BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; FILTER; HEART ATRIUM FIBRILLATION; HEART MUSCLE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFLAMMATORY DISEASE; LEUKAPHERESIS; MAJOR CLINICAL STUDY; MYOCARDITIS; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SCORING SYSTEM; SURGICAL RISK; SYSTEMIC DISEASE; THROMBOCYTE COUNT;

ANIMALS; ATRIAL FIBRILLATION; BLOOD CELL COUNT; CARDIOPULMONARY BYPASS; COHORT STUDIES; COMPLEMENT C3A; CORONARY ARTERY BYPASS; HEART DISEASES; HUMANS; INTERLEUKIN-2; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; PLATELET COUNT; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 36749085139     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659107084146     Document Type: Article

References (32)

1. Aranki SF, Shaw DP, Adams DH et al. Predictors of atrial fibrillation after coronary artery surgery. Current trends and impact on hospital resources. Circulation 1996; 94: 390-97.
2. Creswell LL, Schuessler RB, Rosenbloom M, Cox JL. Hazards of post-operative atrial arrhythmias. Ann Thorac Surg 1993; 56: 539-49.
3. Almassi GH, Schowalter T, Nicolosi AC et al. Atrial fibrillation after cardiac surgery: a major morbid event? Ann Surg 1997; 226: 501-11.
4. Mathew JP, Parks R, Savino JS et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. J Am Med Assoc 1996; 276: 300-06.
5. DiDomenico RJ, Massad MG. Pharmacologic strategies for prevention of atrial fibrillation after open heart surgery. Ann Thorac Surg 2005; 79: 728-40.
6. Dunning J, Treasure T, Versteeg M, Nashef SAM. Guidelines on the prevention and management of de novo atrial fibrillation after cardiac and thoracic surgery. Eur J Cardiothorac Surg 2006; 30: 852-72.
7. Jayam VKS, Flaker GC, Jones JW. Atrial fibrillation after coronary bypass: etiology and pharmacologic prevention. Cardiovasc Surg 2002; 10: 351-58.
8. Chung MK. Cardiac surgery: post-operative arrhythmias. Crit Care Med 2000; 28(10 Suppl): N136-44.
9. Fuster V, Ryden LE, Asinger RW et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2001; 38: 1231-66.
10. Koch CG, Li L, Van Wagoner DR, Duncan AI, Gillinov AM, Blackstone EH. Red cell transfusion is associated with an increased risk for post-operative atrial fibrillation. Ann Thorac Surg 2006; 82: 1747-56.
11. Amar D, Goenka A, Zhang H, Park B, Thaler HT. Leukocytosis and increased risk of atrial fibrillation after general thoracic surgery. Ann Thorac Surg 2006; 82: 1057-61.
12. Sutton SW, Patel AN, Chase VA et al. Clinical benefits of continuous leukocyte filtration during cardiopulmonary bypass in patients undergoing valvular repair or replacement. Perfusion 2005; 20(1): 21-9.
13. Toumpoulis IK, Anagnostopoulos CE, Swistel DG, DeRose JJ Jr. Does EuroSCORE predict length of stay and specific post-operative complications after cardiac surgery? Eur J Cardiothorac Surg 2005; 27(1): 128-33.
14. Wendel HP, Ziemer G. Coating techniques to improve hemocompatibility of artificial devices used for extracorporeal circulation. Eur J Cardiothorac Surg 1999; 16: 342-50.
15. Repo H, Jansson SE, Leirisalo-Repo M. Flow cytometric determination of CD11b upregulation in vivo. J Immunol Methods 1993; 164: 193-202.
16. Ommen SR, Odell JA, Stanton MS. Current concepts: atrial arrhythmias after cardiothoracic surgery. N Engl J Med 1997; 336: 1429-34.
17. Bruins P, te Velthuis H, Yazdanbakhsh AP et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with post-operative arrhythmia. Circulation 1997; 96: 3542-48.
18. Goette A, Juenemann G, Peters B et al. Determinants and consequences of atrial fibrosis in patients undergoing open heart surgery. Cardiovasc Res 2002; 54: 390-96.
19. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation post-operatively. Am J Cardiol 2004; 93: 1176-78.
20. Gunaydin S. Clinical significance of coated extracorporeal circuits: a review of novel technologies. Perfusion 2004; 19: S33-41.
21. Gunaydin S. Emerging technologies in biocompatible surface modifying additives: quest for physiologic cardiopulmonary bypass. Curr Med Chem- Cardiovascular & Hematologic Agents 2004; 2: 187-96.
22. Scholz M, Simon A, Matheis G et al. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 2002; 51(7): 363-68.
23. Baksaas ST, Flom-Halvorsen HI, Ovrum E et al. Leukocyte filtration during cardiopulmonary reperfusion in coronary artery bypass surgery. Perfusion 1999; 14: 107-17.
24. Sahlman A, Ahonen J, Salo JA, Ramo OJ. No impact of a leukocyte depleting arterial line filter on patients recovery after cardiopulmonary bypass. Acta Anaesthesiol Scand 2001; 45(5): 558-63.
25. Gunaydin S, Sari T, McCusker K et al. Clinical evaluation strategic leukofiltration with surface modification: enhanced preservation or fantasy. Filtration 2005; 1(1): 57-67.
26. Fransen E, Maessen J, Dentener M, Senden N, Buurman W. Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 1999; 116: 1233-39.
27. Aviles RJ, Martin DO, Apperson-Hansen C et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-10.
28. Nohé B, Kiefer RT, Ploppa A, Haeberle HA, Schroeder TH, Dieterich HJ. The effects of fresh frozen plasma on neutrophil-endothelial interactions. Anesth Analg 2003; 97: 216-21.
29. Gunaydin S, Farsak B, Kocakulak M, Sari T, Yorgancioglu C, Zorlutuna Y. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)-coated extracorporeal circuits. Ann Thorac Surg. 2002; 74(3): 819-24.
30. Hayashi Y, Sawa Y, Fukuyama N et al. Leukocyte depleted terminal blood cardioplegia provides superior myocardial protective effects in association with myocardium derived nitric oxide and peroxynitrite production for patients undergoing prolonged aortic crossclamping for more than 120 minutes. J Thorac Cardiovasc Surg 2003; 126: 1813-21.
31. Roth M, Kraus B, Scheffold T, Reuthebuch O, Klovekorn WP, Bauer EP. The effect of leukocyte depleted blood cardioplegia in patients with severe left ventricular dysfunction: a randomized, double blind study. J Thorac Cardiovasc Surg 2000; 120: 642-50.
32. Aldea GS. Invited commentary. Ann Thorac Surg 2005; 79(6): 2038-39.